Compare MIGI & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | GOVX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.0M |
| IPO Year | 2013 | N/A |
| Metric | MIGI | GOVX |
|---|---|---|
| Price | $2.69 | $1.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $200.00 |
| AVG Volume (30 Days) | 46.6K | ★ 129.8K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,571,720.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.12 |
| 52 Week High | $15.80 | $4.40 |
| Indicator | MIGI | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 51.49 |
| Support Level | $0.39 | $0.55 |
| Resistance Level | $3.50 | $4.40 |
| Average True Range (ATR) | 0.25 | 0.20 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.12 | 88.89 |
Mawson Infrastructure Group Inc is a digital infrastructure provider with diversified operations across Cryptocurrency Mining and Digital Asset Management. Its mission is to build a bridge between the rapidly emerging digital asset industry and traditional capital markets, with a focus on shareholder returns. The Company has three primary businesses: digital currency or Bitcoin self-mining, customer co-location and related services, and energy markets. It operates in a single segment surrounding its digital currency mining operation.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.